Evommune’s EVO756 Fails Phase 2b Trial in Chronic Spontaneous Urticaria, Development Discontinued

Evommune reported EVO756 failed to meet its primary endpoint in the Phase 2b CSU trial. The company is discontinuing development in urticaria but advancing the drug in atopic dermatitis with data expected in Q3 2026.